

## Index

- abstinence, 264
  - capacity to choose abstinence-oriented treatment, 114–15
- acamprosate, 63, 69, 73, 241
- acetylation, 54
- addiction, 7–10, 19–20, 264, *see also*
  - dependence
  - behavioural, 23, 46
  - clinical understanding of, 21–3
  - cycle of, 22, 31
  - definition, 20, 100
  - ethical principles in treatment, 97–102
    - autonomy, 99–101
    - minimum conditions for ethical treatment, 102–3
    - public good, 101–2
  - folk understanding of, 21
  - genetic basis. *See* genetic contribution to addiction
  - medicalisation of, 230–2, 253–4
  - models of, 28–34
    - brain disease model, 8, 27–8, 31, 100–1, 244–7
    - hedonic models, 45
    - moral (sceptical) model, 28–31, 113–14
    - neurobiological models, 31–3
  - molecular targets of addictive drugs, 63
  - neuroanatomy of, 36–8
  - social factors, 133, *see also*
    - vulnerability
  - social response to, 26–8
- addiction ‘cures’, 181–5, *see also*
  - pharmacotherapy; treatments
  - avoiding future errors, 195–6
  - early history, 181–2
  - Keeley Cure, 182–3
  - neurobiologically inspired cures, 185–90
    - ibogaine therapy, 186–7
    - neurosurgical treatments, 187–90
    - ultra-rapid opioid detoxification (UROD), 187
  - regulation, 183
  - withdrawal treatments, 183–5
- addiction neuroethics, 7, *see also*
  - neuroethics
  - challenges, 256–8
  - future directions, 258–9
- addiction research, 146–8, 160, 248, *see also* neuroscience
  - drug administration, 153–60
    - reasons for, 154–6
    - risks of, 156–7
  - treated versus untreated addicts, 157–8
- informed consent, 148–50
  - capacity to consent, 157–8, 160
  - obtaining consent, 159–60
- motivations for participation, 150
- payment of participants, 150–2
- privacy and confidentiality issues, 152–3
- recruitment of participants, 158–60
- admission guidelines, 117–19

- adolescents, 58–9
  - vaccination against addiction, 207
- agent, 264
- agonist treatments, 62–6
  - GABA agonists, 73–4
  - partial agonists, 67–8, 71
- agonists, 65, 264
  - partial agonists, 67, 270
- AIDS treatment, 127–8
- alcohol
  - burden of abuse, 25–6
  - engineering safer alternatives, 241
  - predictive testing for dependence, 200
  - prevalence of use, 23
  - social policies, 27
    - industry influence, 236
    - withdrawal treatment, 69
- alcohol dehydrogenase (ADH), 71
- aldehyde dehydrogenase 2 (ALDH2) gene, 56
- alleles, 264
- amygdala, 264
- anhedonia, 264
- animal models, 113, 256–7
- anonymity, addiction research and, 152–3
- Antabuse, 71
- antagonist treatments, 46, 66–7, 70–1
- antagonists, 66, 264
- antiretroviral (ARV) therapy, 127–8
- anterior cingulate gyrus (aCG), 47, 265
- anticonvulsant therapies, 74
- antipsychotic treatment, 185
- anti-reward pathway, 50, 265
- anxiety, 58
- aripiprazole, 71
- associative learning, 265
- attention deficit hyperactivity disorder (ADHD), 58
- Australia
  - burden of disease related to drug use, 25
  - cannabis decriminalisation, 238
  - naltrexone implant experience, 176
  - prevalence of drug use and addiction, 23–4
- autonomy, 91–2, 249, 265, *see also* informed consent
  - addiction effects on, 99–101
  - overriding, 98
  - respect for, 86, 90–2, 94, 272
  - restoration of, 92
    - coerced treatment using drug implants, 176–9
- aversive model, 45
- baclofen, 74
- behavioural addictions, 23, 46
- belladonna treatment of withdrawal, 184
- beneficence, 92, 265
  - addiction research, 147
- bioprediction of addiction liability, 197–8
  - genetic tests, 198–200
    - commercialisation of, 204–6
    - genetic discrimination issue, 202–4
    - use of results to increase abstinence, 200–2
  - neuroimaging studies, 207–8
- blame, 5
- body awareness, 50
- brain disease model, 8, 27–8, 31, 32, 244–7
  - autonomy implications, 100–1
  - implications for capacity to consent, 109–10
  - potential consequences of, 33, 244–7
- bromide sleep treatment (BST), 184
- buprenorphine, 67, 174, 265
- bupropion, 70, 71
- burden of disease (BOD)
  - drug and alcohol use related, 25–6
  - psychiatric disorders, 4
- California, cannabis policy, 239–40
- candidate genes, 55

- cannabinoids, 74  
 cannabis legalisation, 237–40  
 capacity to choose, 8, 32, 91, *see also*  
   autonomy; self control  
   addiction effects, 108–13, 261  
   abstinence-oriented treatment,  
     114–15  
   implications for consent to  
     treatment, 115–17  
   sceptical view, 113–14  
 cognitive capacity, 106  
 volitional capacity, 106, 107, *see also*  
   informed consent  
 categorical imperative, 88  
 CB1 cannabinoid receptor, 74  
 cerebrum, 265  
 children, vaccination of, 206  
 chlorpromazine treatment, 185  
 choice, 28–30, *see also* capacity to choose  
   constrained choices, 141–2, 251  
 chromatin remodelling, 54  
 cigarette smoking. *See* nicotine  
   dependence; tobacco  
 clonidine, 69  
 CNS depressants, 265  
 coerced treatment, 129–30, 134–5, 144,  
   246–7  
   approaches to, 135–6  
   constrained choices, 141–2  
   depot naltrexone use to restore  
     autonomy, 176–9  
   effectiveness, 140–1  
   ethical issues, 142  
   compulsory treatment, 142–4  
   justifications for, 138–42  
   legal coercion, 136–8  
   neuroenhancement, 218–19  
   pregnant women, 132  
   vaccination, 171–2  
 coercion, 265  
 cognitive enhancement, 6, 75, 214–16,  
   *see also* neuroenhancement  
 cognitive impairment, 47–50, 58  
 communitarian ethics, 88–9  
 comorbid conditions, 133  
 competence, 91, *see also* capacity to  
   choose  
 compulsion, 47, 265  
 compulsory treatment, 142–4, *see also*  
   coerced treatment  
 conditioned incentive-learning, 265  
 confidentiality, 147, 252, 265  
   addiction research and, 152–3  
 consequentialism, 88  
 constrained choices, 141–2, 251  
 convulsive therapy, 185  
 corrected feedback, 107, 119  
 cortex, 266  
 corticotropin-releasing factor  
   (CRF), 75  
 craving, 47, 70, 266  
   incubation of, 268  
   perception of, 50  
   pharmacotherapy, 169–70  
     ethical issues, 169–70  
     reduction of cue-conditioned  
       craving, 72  
   research participation and, 159  
 crime, 24  
 cycle of addiction, 22, 31  
 decriminalisation of illicit drugs, 132  
   cannabis, 237–40  
 deep brain stimulation (DBS), 78–9,  
   190–5  
   costs of, 195  
   risks of, 193–4  
 delirium tremens, 69, 266  
 dendritic spines, 54  
 deontology, 88  
 dependence, 20, *see also* addiction  
   alcohol, predictive testing for, 200  
   heroin, 62–5  
   nicotine, 76, 200–2

- dependence (*cont.*)  
   genetic screening to increase  
     abstinence, 200–2  
     pharmacogenetic treatment issues,  
       209–11  
   physical, 20, 264, 271  
   psychological, 20, 264  
   vulnerability to, 28
- depot injections, 78, 174
- depression, 51, 58
- detoxification, 69
- dignity, 91, 266
- dimensional disorder, 266
- direct to customer (DTC) genetic  
 tests, 204–6
- discontinuation syndrome, 20, *see also*  
 withdrawal
- discrimination, 9, 259  
   genetic discrimination, 202–4
- disease model. *See* brain disease model
- distributive justice, 93, 266
- disulfiram, 63, 71
- dizocilpine, 73
- dopamine, 39, 46, 266  
   agonists, 65–6  
   antagonists, 46, 70–1  
   environmental interactions, 57–8  
   learning and, 40–3  
   partial agonists, 71, 72  
   reward system and, 40–4  
   stress effects, 51  
   withdrawal and, 130
- dopaminergic treatment, 70
- drug addiction. *See* addiction
- drug cues, 266
- drug implants, 78, 174  
   coerced use to restore autonomy, 176–9  
   naltrexone, 175, 176
- drug policy, 122, 237–40, 248  
   neuroenhancement drug regulation,  
     223–5  
   neuroscience implications, 250
- drug priming, 266
- drug use. *See also* drug addiction;  
 opioid use  
   alcohol, 23  
   Australia, 23–4  
   burden of, 25–6  
     social costs, 25  
   harm related to, 24–5  
   lessons for neuroenhancement, 221–3  
   reduction using incentives, 262  
   social response to, 26–8  
   tobacco, 23
- dynorphin, 75
- dysphoria, 266
- electroconvulsive therapy (ECT), 185
- empirical neuroethics, 260
- encephalin, 267
- endophenotype, 266
- endorphins, 267
- enhancement. *See* cognitive  
 enhancement;  
 neuroenhancement
- epigenetic changes, 53–5
- epigenetics, 267
- equality, 91, 93, 123, 267  
   access to neuroenhancement  
     technologies, 219–20
- equivalence, 267
- ethics, 87–90, 267, *see also* neuroethics  
   agent-based approaches, 88–9  
   challenges, 256–8  
   duty-based approaches, 87–8  
   ethical principles in addiction  
     treatment, 97–102  
       autonomy, 99–101  
       minimum conditions for ethical  
       treatment, 102–3  
       public good, 101–2  
   of care, 89
- euphoria, 267
- executive control, 47–50, 267

- fatalism, 101, 267  
 feminist ethics, 89  
 flumazenil, 67  
 forebrain, 267  
 freedom, 267  
 frontal cortex, 267  
 functional magnetic resonance imaging (fMRI), 267
- GABA agonists, 73–4  
 genetic contribution to addiction, 7  
   pharmacogenetic treatment, 75–6  
   vulnerability, 32, 55–7  
     interaction with environmental factors, 57–9
- Genetic Information Non-Discrimination Act, USA, 6, 204
- genetic information security, 6, 202–4  
 genetic pleiotropy, 203  
 genetic tests of addiction liability, 198–200  
   commercialisation of, 204–6  
   genetic discrimination issue, 202–4  
   use of results to increase abstinence, 200–2
- GHB (gamma-hydroxybutyric acid), 242  
 glutamate, 73, 74
- habits, 46–7  
 harm reduction, 267  
   approaches, 240–2
- HCV infection  
   coerced treatment and, 136–7  
   risk for prisoners, 130–1
- hedonic models, 45  
 heroin, 268, *see also* opioid use  
   pharmacotherapy for dependence, 62–5  
   prescription trials, 268
- hibernation therapy, 185  
 hippocampus, 268
- histones, 54  
 HIV infection, 127–8  
   coerced treatment and, 136–7  
   risk for prisoners, 130–1
- homeostasis, 268
- human rights, 94–5, 268, *see also* rights of addicted individuals  
   addicted pregnant women, 131–2  
   addicted prisoners, 130–1  
   future challenges, 132–3  
   legal coercion and, 129–30
- Huntington's disease, 200  
 hypothalamus, 268
- ibogaine therapy, 186–7  
 immunotherapies, 76–7, 170–3  
 impulse inhibition, 268  
 incentive sensitisation, 268  
 incentives to reduce drug use, 262  
 information security, 6, 252  
 informed consent, 105–6, 119–20, 268, *see also* autonomy; capacity to choose  
   addiction impact on capacity, 108–13, 261  
   abstinence-oriented treatment, 114–15  
   implications, 115–17  
   sceptical view, 113–14
- addiction research  
   participation, 147, 148–50, 157–8, 160  
   obtaining consent, 159–60
- brain disease model implications, 109–10  
 conclusions, 250–1  
 deep brain stimulation (DBS), 194  
 neurosurgical procedures, 190  
 requirements for, 107, 118  
 research on, 106–8  
 role in addiction treatment, 106–8  
 vaccination, 171–2

- insula, 50, 269  
 interoception, 50, 269
- justice, 92–3  
   distributive, 93, 266
- Keeley Cure, 182–3
- learning, 46–7  
   associative, 265  
   conditioned incentive, 265  
   dopamine and, 40–3
- legal coercion, 136–8, *see also* coerced treatment
- legalisation of illicit drugs, 132  
   cannabis, 237–40
- libertarianism, 140
- liberty, 102, 269
- limbic system, 269
- lofexidine, 69
- long-acting medications, 77–8
- long-term depression (LTD), 52–3, 269
- long-term potentiation (LTP), 52–3, 269
- maintenance therapy, 68, 125–6, 269
- media, 254–6
- medicalisation of addiction, 230–2, 269
- memory manipulators, 75
- mental illnesses. *See* psychiatric disorders
- methadone, 65  
   maintenance therapy (MMT), 65, 125–6
- methylation, 54
- methylphenidate, 215, 216
- minimal risk, 269
- modafinil, 75, 215, 216
- moral (sceptical) model, 28–31, 113–14
- mortality, drug-related, 24
- motivation, 35, 269, *see also* reward system  
   anti-craving drug effects, 169–70
- mu-opioid receptor (MOR), 45–6,  
   72, 269
- N-acetylcysteine (NAC), 73
- naloxone, 45, 269
- naltrexone, 45, 67, 73, 76, 143, 168, 269  
   long-term effects on motivation, 169  
   sustained-release technologies, 174  
     coerced use to restore autonomy,  
     176–9  
   implants, 175, 176
- naturalistic fallacy, 96
- needle exchange programs, 126–7
- negative reinforcement, 22
- Netherlands, cannabis policy, 238–9
- neuroanatomy of addiction, 36–8
- neurobiological models, 31–2, *see also*  
   brain disease model  
   potential consequences of, 32–3
- neurocognitive tests, 80, 211–13
- neuroenhancement, 214–16  
   drug regulation, 223–5  
   lessons from recreational drug use,  
   221–3  
   problems with, 216–21  
     coercion, 218–19  
     equity of access, 219–20  
     naturalistic objections, 220–1  
     safety and efficacy concerns, 217–18
- neuroessentialist approach, 2
- neuroethics, 4–7, 85–7  
   challenges, 256–8  
   empirical, 260  
   future directions, 258–9  
   pragmatic approach, 95–7
- neuroimaging, 79–80  
   biopredictive use, 207–8  
   costs, 208  
   use in personalised treatment, 211–13
- neuropsychological studies, 80–1, 113
- neuroscience, 1–4, 229, 244–7  
   challenges, 256–8  
   issues, 5–6  
   limitations, 244–7, 249  
   media and, 254–6

- potential benefits, 4–5, 14–15
  - treatments, 8
- public health policy implications, 229–30
- research findings, 59–60, *see also*
  - addiction research
  - subversive use of, 234–7
- neurosurgery, 78, 187–90, 246
- neurotransmitter, 270
- NicoTest*, 76
  - evaluation, 209–10
- nicotine dependence. *See also* tobacco
  - genetic screening to increase
    - abstinence, 200–2
  - pharmacogenetic test, 76
  - pharmacogenetic treatment issues, 209–11
  - vaccines, 200–2
- nicotine replacement therapy (NRT), 62
- N-methyl-D-aspartic acid (NMDA)
  - receptor, 73
  - antagonists, 73
- non-maleficence, 92, 270
  - addiction research, 147
- noradrenaline, 39
- nucleus accumbens (NAcc), 40, 270
  - deep brain stimulation (DBS), 192–3
  - reward system and, 40–4
  - surgical ablation, 189
- opioid naiveté, 270
- opioid system, 45–6
  - pharmacological blocking, 72–3
- opioid use. *See also* drug use capacity to
  - consent to treatment, 110–12
  - disease model of dependence, 27–8
  - harm related to, 24
  - pharmacotherapy, 28
    - agonist treatment, 62–5
  - ultra-rapid opioid detoxification (UROD), 128, 187, 245
    - vulnerability to dependence, 28
    - withdrawal, 69–70
- orbitofrontal cortex (OFC), 47, 49, 270
- overdose, 270
- oxytocin, 215
- Parkinson’s disease (PD), 192, 193
- partial agonist treatments, 67–8, 71
  - cue-conditioned cravings, 72
- partial agonists, 67, 270
- paternalism, 92, 98, 270
  - hard paternalism, 138
  - justification for coerced treatment, 138–9
  - soft paternalism, 138, 139
- payment for research participation, 150–2
- personalised treatment, 208–13
  - neuroimaging applications, 211–13
  - pharmacogenetic, 209–11
- pharmacogenetic treatment, 75–6, 209–11
- pharmacogenetics, 270
- pharmacotherapy, 28, 62, *see also*
  - treatments
- approaches, 63
- craving, 70–2, 169–70
  - ethical issues, 169–70
  - reduction of cue-conditioned craving, 72
  - reduction of drug reinforcement, 70–1
- current treatments, 64
- duration of treatment, 68–9
- ibogaine therapy, 186–7
- immunotherapies, 76–7, 170–3
- investment in development, 168–9
- long-acting or sustained-release medications, 77–8, 173–6
- maintenance therapy, 68, 125–6, 269

- pharmacotherapy (cont.)  
 novel approaches, 76  
 relapse prevention, 170–9  
 research and development issues, 168–9  
 relapse treatment, 70–2  
 stress response, 75  
 substitution treatment, 65, 68, 125–6  
 treatments related to reward system, 72–5  
 amino acid neurotransmitters, 73–4  
 cannabinoids, 74  
 cognitive enhancers, 75  
 memory manipulators, 75  
 opioid system, 72–3  
 treatments that block drug binding, 62–9  
 agonists, 62–6  
 antagonists, 66–7  
 partial agonists, 67–8  
 withdrawal symptoms, 69–70  
 physical dependence, 20, 264, 271  
 pluralistic approach, 95–6  
 policy. *See* drug policy; public health policy  
 positive reinforcement, 21  
 positron emission tomography (PET), 270  
 pragmatic approach, 95–7  
 preclinical trials, 271  
 prediction error signal, 43  
 prefrontal cortex (PFC), 49, 271  
 pregnant women, 131–2, 253  
 prevalence of drug use  
 alcohol, 23  
 Australia, 23–4  
 tobacco, 23  
 preventive medicine, 197, *see also* vaccines  
 principlism, 90–4  
 relationship between principles, 93–4  
 prison costs, 9, 24  
 prisoners, 130–1, 252–3  
 privacy, 147, 252, 271  
 addiction research and, 152–3  
 prohibition policies, 26–7  
 neuroenhancement technologies, 223, 224  
 propranolol, 75  
 psychiatric disorders, 2–4  
 burden of, 4  
 psychological dependence, 20, 264  
 psychosocial approaches, 81, 232–3  
 public good, 86, 99, 271  
 addiction and, 101–2  
 communitarianism, 88–9  
 justification for coerced treatment, 139  
 versus autonomy, 98  
 public health policy, 229–30, 232–7, 248, *see also* drug policy  
 competing strategies, 233–4  
 epidemiological modelling, 261–2  
 industry influence, 234–7  
 public understanding, 249, 259–60  
 media role, 254–6  
 receptor, 271  
 regulation of neuroenhancement  
 drugs, 223–5  
 reinforcement, 21, 271  
 dopamine effects, 40–3  
 natural reinforcers, 40, 270  
 negative, 22  
 pharmacological reduction of drug  
 reinforcement, 70–1  
 reinforcers, 271  
 reinstatement, 271  
 relapse, 271  
 learning and, 46–7  
 prevention, 66, 69, 170–9, 272  
 drug vaccines, 170–3  
 stress effects, 50–1  
 treatment, 70–2  
 triggers, 80  
 relationship-based ethics, 89



- research. *See* addiction research
- responsibility, 5
- reuptake, 272
- reward, 272
- reward systems, 36, 37
- dopamine and, 40–4
  - pharmacological blocking, 70–1, 72–5
    - amino acid neurotransmitters, 73–4
    - cannabinoids, 74
    - memory manipulators, 75
    - opioid system, 72–3
  - reward pathway, 272
  - stress effects, 51
- rights, 272
- rights of addicted individuals, 121–2, 123–4, 247–8, *see also* human rights
- access to treatment, 124–8
  - effective treatment, 125–6
  - harm reduction measures, 126–7
  - HIV treatment, 127–8
  - legal coercion and, 129–30
  - pregnant women, 131–2
  - prisoners, 130–1
  - unevaluated and risky treatments, 128–9
- rimonabant, 67, 74
- Ritalin, 215, 216
- saliency, 43, 272
- sceptical view, 28–31, 113–14
- scopolamine intoxication, 184
- selective serotonin reuptake inhibitors (SSRIs), 20
- self control, 2, 10, *see also* autonomy; capacity to choose
- loss of, 19
- self-administration, 272
- serotonin, 39
- smoking. *See* nicotine dependence; tobacco
- snus, 261, 272
- social coercion, 135
- social harm reduction, 9
- social policies. *See* public health policy
- social response to drug use, 26–8
- stigma, 5, 259
- stigmatisation, 152
- stimuli, 272
- stress, 50–1
- neuroadaptations to, 51
  - pharmacotherapy, 75
- striatum, 273
- subject payments for research participation, 150–2
- Suboxone, 67, 273
- substance abuse disorder, 20
- substitute, 273
- substitution treatment, 65, 68, 125–6
- sustained-release medications, 77–8, 173–6
- advantages, 174
  - coerced use to restore autonomy, 176–9
  - ethical issues, 174–5
- symptomatic support, 69
- synapse, 273
- synaptic plasticity, 52–3, 273
- tapered withdrawal, 68, 273
- taxation policies, 26
- technological fix, 231
- Tempol, 241
- thalamus, 273
- thalidomide, 241
- therapeutic misconception, 116, 148, 273
- tiagabine, 74
- tobacco. *See also* nicotine dependence
- genetic screening to increase abstinence, 200–2
  - prevalence of use, 23
  - social policies, 27, 202
  - industry influence, 235–6
- tolerance, 22, 264, 273

- topiramate, 74  
 Towns–Lambert treatment, 184  
 transcranial magnetic stimulation (TMS), 79  
 transporter, 273  
 treatments, 8, *see also* pharmacotherapy  
   abstinence-oriented, capacity to consent, 114–15  
   admission guidelines, 117–19  
   case for medical treatment, 124–5  
   compulsory treatment, 142–4, *see also* coerced treatment  
   consent to. *See* informed consent  
   deep brain stimulation (DBS), 78–9, 190–5  
   ethical principles in, 97–102  
     autonomy, 99–101  
     minimum conditions for ethical treatment, 102–3  
     public good, 101–2  
   history of addiction ‘cures’, 181–5  
   history of addiction ‘cures’  
     early history, 181–2  
     Keeley Cure, 182–3  
     regulation, 183  
     withdrawal treatment, 183–5  
   legal coercion. *See* coerced treatment  
   neurosurgery, 78, 187–90, 246  
   new developments, 165–6  
   personalised treatment, 208–13  
     neuroimaging applications, 211–13  
     pharmacogenetic treatment, 209–11  
   psychosocial approaches, 81  
   rate of treatment, 26  
   right of access to, 124–8, 250  
     effective treatment, 125–6  
     harm reduction measures, 126–7  
     HIV treatment, 127–8  
     safety requirement, 250  
   transcranial magnetic stimulation (TMS), 79  
   unevaluated and risky treatments, 128–9  
 twins, 273  
 ultra-rapid opioid detoxification (UROD), 128, 187, 245, 274  
 Universal Declaration of Human Rights (UDHR), 94  
 utilitarianism, 88, 274  
 utility, 88  
 vaccines, 76–7, 170–3, 206–7  
   children, 206  
   ethical issues, 171–3  
   high risk adolescents, 207  
   nicotine, 200–2  
   preventive use, 252  
 valproate, 74  
 varenicline, 67, 68  
 ventral tegmental area (VTA), 40, 274  
 vigabatrin, 74  
 violent behaviour, 24  
 vulnerability, 55–9, 264  
   bioprediction, 197–8  
     genetic tests, 198–200  
     neuroimaging studies, 207–8  
   genetic basis, 32, 55–7  
     interaction with environmental factors, 57–9  
   opioid dependence, 28  
 withdrawal, 20, 22, 264, 274  
   capacity to consent and, 115  
   discontinuation syndrome, 20  
   dopamine and, 130  
   history of treatments, 183–5  
   orbitofrontal cortex changes, 47  
   pharmacotherapy of, 69–70  
   prisoners, 130  
   tapered, 68, 273